Hemoglobin Rahere, a human hemoglobin variant with amino acid substitution at the 2,3-diphosphoglycerate binding site. Functional consequences of the alteration and effects of bezafibrate on the oxygen bindings.

J Sugihara; T Imamura; S Nagafuchi; J Bonaventura; C Bonaventura; R Cashon

doi:10.1172/JCI112072

Find articles by Sugihara, J. in: PubMed | Google Scholar

Find articles by Imamura, T. in: PubMed | Google Scholar

Find articles by Nagafuchi, S. in: PubMed | Google Scholar

Find articles by Bonaventura, J. in: PubMed | Google Scholar

Find articles by Bonaventura, C. in: PubMed | Google Scholar

Find articles by Cashon, R. in: PubMed | Google Scholar

Published in Volume 76, Issue 3 on September 1, 1985
J Clin Invest. 1985;76(3):1169–1173. https://doi.org/10.1172/JCI112072.
© 1985 The American Society for Clinical Investigation

Published September 1, 1985 - Version history

We encountered an abnormal hemoglobin (Rahere), with a threonine residue replacing the beta 82 (EF6) lysine residue at the binding site of 2,3-diphosphoglycerate, which was responsible for overt erythrocytosis in two individuals of a Japanese family. Hemoglobin Rahere shows a lower oxygen affinity on the binding of 2,3-diphosphoglycerate or chloride ions than hemoglobin A. Although a decrease in the positive charge density at the binding sites of 2,3-diphosphoglycerate in hemoglobin Rahere apparently shifts the allosteric equilibrium toward the low affinity state, it greatly diminishes the cofactor effects by anions. The oxygen affinity of the patient's erythrocytes is substantially lowered by the presence of bezafibrate, which combines with sites different from those of 2,3-diphosphoglycerate in either hemoglobin Rahere or hemoglobin A.